• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Baby boomers trend toward higher drug utilization


As the first of the baby boomers become eligible for Medicare in 2011, the healthcare system is bracing itself to support added burdens on drug utilization

Key Points

RISK PROPOSITIONS will likely change as a reflection of the aging of America, and there are several dynamics to consider. One difference between the baby boomers and adults over age 65, for example, is that the younger group is more likely to address health issues before they become complex, while those over 65 might ignore a diagnosis of high cholesterol or hypertension.

As the first of the baby boomers become eligible for Medicare in 2011, the healthcare system is bracing itself to support added burdens on drug utilization and costs. Add longer life spans and expensive biologics, and payers have cause for alarm.

Fifty percent of seniors take eight or more prescriptions on average, according to CVS Caremark. Seventy percent of 50- to 64-year-olds report having been diagnosed with one or more chronic conditions, and nearly half have two or more, the latter consuming more than 3.5 times the average cost for those with no chronic conditions, as reported by AARP.

Top contributors to the cost trend among baby boomers include diabetes (28.3%), rheumatological (14.6%), and asthma and COPD drugs (14.3%), according to the 2010 Medco Drug Trend Report. Medco also found that as many as 75% of insured Americans in the baby boomer group are currently taking at least one medication for a chronic condition, and more than half are regularly taking three or more drugs.

The report also indicates net plan costs for 50- to 64-year-olds of $1,243 annually.

A study by Quintiles Consulting, a biopharmaceutical services company, looked at new patient prescriptions, total prescriptions and out-of-pocket costs for five age groups: age 18 years or younger; 19 to 35; 36 to 54; 55 to 64; and older than 65. Each were researched for cholesterol, diabetes, depression, hypertension and pain.

Results indicate that 55- to 64-year-olds actually rank second in new patient prescriptions (after the group of 36- to 54-year-olds) and rank third in total prescriptions and out-of-pocket costs (OOP).

"We initially hypothesized that the age 55 to 64 group would have the highest total drug and out-of-pocket costs, so it was certainly surprising that it did not," says Bryan Sepulveda, a consultant with Quintiles. "One may speculate that this may have been a result of the drug classes chosen since more and more younger individuals are being affected by depression and pain. In addition, the Medicare group has the lowest OOP costs than any other group because most private insurance exacts a greater degree of patient cost sharing."


Medco's Dr. Eisenberg says that the most important issue to watch is the increase in brand-name prices.

The average price of branded prescription drugs rose by an annual rate of 9.3% in 2009, the largest growth rate since 2002, according to a report released by AARP. He estimates that aging's impact on expenditures will increase 0.3% to 0.6% annually, making a significant dent 20 years hence.

Dr. Eisenberg is optimistic about the Patient Protection and Affordable Care Act (PPACA). Some provisions could lower costs: phase-out of the Part D donut hole by 2020; the development of accountable care organizations by 2012; and the launch of health insurance exchanges, which will spread risk across a larger pool of individuals.

He says comparative effectiveness research is also an effective tool to help healthcare stakeholders make wiser decisions on how they manage the pharmacy benefit. Personalized medicine is another potential means to ensure more appropriate drug use and helping to keep costs at bay, Dr. Eisenberg says. However, he questions whether insurers will pay for the testing that goes along with it. Personalized medicine has to show return on investment, he says.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.